USPTO serial 86837812
ABCLONAL TECHNOLOGY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 30, 2016
- Examiner
- COLEMAN, CIMMERIAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with ABCLONAL TECHNOLOGY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $2,550
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Wuhan ABclonal Biotechnology Co., Ltd
Wuhan, CN
Other trademarks owned by Wuhan ABclonal Biotechnology Co., Ltd
Wuhan ABclonal Biotechnology Co., Ltd
Wuhan, CN
Other trademarks owned by Wuhan ABclonal Biotechnology Co., Ltd
Wuhan ABclonal Biotechnology Co., Ltd
Wuhan, CN
Other trademarks owned by Wuhan ABclonal Biotechnology Co., Ltd
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Kevin L. Russell
Kevin L. Russell CHERNOFF VILHAUER LLP111 SW COLUMBIA STREETSUITE 1080PORTLAND, OR 97201Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Biochemicals, namely, polyclonal antibodies for in vitro scientific or research use; diagnostic kits consisting of polyclonal antibodies, buffers, and reagents for scientific and research use; biochemicals, namely, polyclonal antibodies for the detection of antigens; diagnostic kits consisting of polyclonal antibodies, buffers, reagents for use in disease testing; biochemicals, namely, custom polyclonal antibodies specifically recognizing antigens provided by customer; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; diagnostic kits consisting of monoclonal antibodies, buffers, and reagents for scientific and research use; biochemicals, namely, monoclonal antibodies for the detection of antigens; biochemicals, namely, custom monoclonal antibodies specifically recognizing antigens provided by customer; Enzyme-linked immunosorbent assay kits comprised of assays and reagents for scientific and research use; chemical reagents, namely, recombinant protein for scientific and research use; chemicals, namely, custom recombinant proteins manufactured for others; biochemical kits consisting of recombinant proteins, buffers, reagents for scientific and research use | ACTIVE | Aug 26, 2013 |
| 005 | Diagnostic kits consisting of monoclonal antibodies, buffers, reagents for use in disease testing; Diagnostic kits consisting of recombinant proteins, buffers, reagents for use in disease testing | ACTIVE | Aug 26, 2013 |
| 042 | custom design and development of polyclonal antibodies specifically recognizing an antigen; custom design and development of kits consisting polyclonal antibodies specifically recognizing an antigen, buffers, reagents for scientific and research use; custom design and development of kits consisting of polyclonal antibodies specifically recognizing an antigen, buffers, reagents for detection of the antigen; custom design and development of monoclonal antibodies specifically recognizing an antigen; custom design and development of kits consisting of monoclonal antibodies specifically recognizing an antigen, buffers, reagents for scientific and research use; custom design and development of kits consisting of monoclonal antibodies specifically recognizing an antigen, buffers, reagents for detection of the antigen; custom design and development of recombinant proteins for others; Custom design and development of enzyme-linked immunosorbent assay kits consisting of polyclonal antibodies recognizing an antigen, buffers, reagents; Custom design and development of enzyme-linked immunosorbent assay kits consisting of monoclonal antibodies recognizing an antigen, buffers, reagents; Custom design and development of recombinant proteins for scientific and research use; Custom design and development of kits consisting of recombinant proteins, buffers, reagents for scientific and research use; Custom design and development of diagnostic kits consisting of recombinant proteins, buffers, reagents for use in disease testing | ACTIVE | Aug 26, 2013 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Wuhan ABclonal Biotechnology Co., Ltd
- Other trademarks owned by Wuhan ABclonal Biotechnology Co., Ltd
- Other trademarks owned by Wuhan ABclonal Biotechnology Co., Ltd
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named ABCLONAL TECHNOLOGY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 14, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 14, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 14, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jan 30, 2026 | NA89 | NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED | — |
| Jan 30, 2026 | RNL1 | REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS) | The trademark registration was renewed for another 10-year term after acceptable maintenance filings. RNL1, RNL2, and RNL3 indicate which renewal cycle (first, second, or third 10-year term) was recorded. The registration remains active. |
| Jan 30, 2026 | 89AG | REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED | The USPTO accepted your combined Section 8 declaration and Section 9 renewal application. The registration is renewed for another 10-year term. The next combined maintenance filing will be due at the following 10-year anniversary. |
| Jan 30, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Oct 27, 2025 | E89R | TEAS SECTION 8 & 9 RECEIVED | — |
| Aug 30, 2025 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Jan 31, 2022 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jan 31, 2022 | C15A | REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Dec 14, 2021 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Sep 13, 2021 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Aug 30, 2021 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 30, 2016 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 14, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 14, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 25, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 6, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 4, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 3, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 3, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 5, 2016 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 5, 2016 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 5, 2016 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2016 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 9, 2015 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Dec 8, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 7, 2015 | NWAP | NEW APPLICATION ENTERED | — |